HPV genotyping from invasive cervical cancer in Chile

International Journal of Gynecology and Obstetrics

Volumn 105, Issue 2, 2009, Pages 150-153

  Roa, Juan Carlos ^a   Garcia, Patricia ^a   Gomez, Jorge ^b   Fernández, Wanda ^c   Gaete, Fancy ^d   Espinoza, Arturo ^e   Lepetic, Alejandro ^f   Suarez, Eugenio ^g  

^a UNIVERSIDAD DE LA FRONTERA   (Chile)

^b GlaxoSmithKline   (Argentina)

^c HOSPITAL SAN BORJA ARRIARÁN   (Chile)

^d Servicio de Medicina Hospital Santiago Oriente Hospital Santiago Oriente Dr Luis Tisné Brousse   (Chile)

^e Citolab Laboratory   (Chile)

^f Estrada dos Bandeirantes   (Brazil)

^g UNIVERSITY OF CHILE   (Chile)

Author keywords

Cervical cancer; Human papillomavirus genotyping; Polymerase chain reaction reverse line blotting assay

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ARTICLE; CANCER INVASION; CHILE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN TISSUE; MIXED INFECTION; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VIRUS INFECTION; VIRUS TYPING; WART VIRUS;

EID: 64449086092     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijgo.2008.12.017     Document Type: Article

References (27)

1. Parkin D.M., Pisani P., and Ferlay J. Global cancer statistics. CA Cancer J Clin 49 1 (1999) 33-64 1
2. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80 6 (1999) 827-841
3. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 2 (2005) 74-108
4. Suarez E., and Prieto M. Cervical cancer: the Chilean perspective: FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynecol Obstet 95 Suppl 1 (2006) S235-S238
5. Munoz N., Bosch F.X., de Sanjose S., Tafur L., Izarzugaza I., Gili M., et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 52 5 (1992) 743-749
6. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical. J Clin Pathol 55 4 (2002) 244-265
7. Munoz N., Bosch F.X., Castellsague X., Diaz M., de Sanjose S., Hammouda D., et al. Against which human papillomavirus types shall we vaccinate and screen? the international perspective. Int J Cancer 111 2 (2004) 278-285
8. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. International biological study on cervical cancer Study Group. Prevalence of human papillomavirus in cervical cancer: a perspective. J Natl Cancer Inst 87 11 (1995) 796-802
9. Melo A., Montenegro S., Hooper T., Capurro I., Roa J.C., and Roa I. Human papilloma virus (HPV) typing in preneoplastic and lesions of the uterine cervix in the IX region-Chile [in Spanish]. Rev Med Chil 131 12 (2003) 1382-1390
10. Ferreccio C., Prado R.B., Luzoro A.V., Ampuero S.L., Snijders P.J., Meijer C.J., et al. Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile. Cancer Epidemiol Biomarkers Prev 13 12 (2004) 2271-2276
11. Aedo S, Melo A, García P, Guzmán P, Capurro I, Roa J. Detección y tipificación de virus papiloma humano en lesiones preneoplásicas del cuello uterino mediante PCR-RFLP. Rev Med Chile 2007;135:167-173.
12. Clifford G.M., Smith J.S., Aguado T., and Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89 1 (2003) 101-105
13. van den Brule A.J., Pol R., Fransen-Daalmeijer N., Schouls L.M., Meijer C.J., and Snijders P.J. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 40 3 (2002) 779-787
14. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 1 (1999) 12-19
15. Walboomers J.M., and Meijer C.J. Do HPV-negative cervical carcinomas exist?. J Pathol 181 3 (1997) 253-254
16. Brink A.A., Snijders P.J., and Meijer C.J. HPV detection methods. Dis Markers 23 4 (2007) 273-281
17. Rolon P.A., Smith J.S., Munoz N., Klug S.J., Herrero R., Bosch X., et al. Human papillomavirus infection and invasive cervical cancer in Paraguay. Int J Cancer 85 4 (2000) 486-491
18. Santos C., Munoz N., Klug S., Almonte M., Guerrero I., Alvarez M., et al. HPV types and cofactors causing cervical cancer in Peru. Br J Cancer 85 7 (2001) 966-971
19. Garcia P., Benavente F., Melo A., Roa I., and Roa J. Effects of fixation over the DNA quality: controlled study with 5 fixatives. Rev Esp Patol 39 3 (2006) 175-179
20. Pretet J.L., Jacquard A.C., Carcopino X., Charlot J.F., Bouhour D., Kantelip B., et al. Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study. Int J Cancer 122 2 (2008) 428-432
21. Melo A., Roa I., Montenegro S., Capurro I., and Roa J.C. Detection of human papilloma virus in cytologic samples or cervix. [in Spanish]. Rev Med Chil 133 6 (2005) 639-644
22. Pirog E.C., Kleter B., Olgac S., Bobkiewicz P., Lindeman J., Quint W.G., et al. Prevalence of human papillomavirus DNA in different histological of cervical adenocarcinoma. Am J Pathol 157 4 (2000) 1055-1062
23. Andersson S., Rylander E., Larsson B., Strand A., Silfversvard C., and Wilander E. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer 37 2 (2001) 246-250
24. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 9580 (2007) 2161-2170
25. Harper D.M., Naud P., Quint W., Dubin G., Jenkins D., and Schuind A. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: Long-term follow-up through 6.4 years in women vaccinated with CERVARIX (GSK's HPV 16/18 AS04 Candidate vaccine). Abstract presented at the Society of Gynecologic Oncologists Annual Meeting on Women's Cancer, Tampa, Florida (March 10 2008)
26. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (2006) 1247-1255
27. Szarewski A. Prophylactic HPV vaccines. Eur J Gynaecol Oncol 28 3 (2007) 165-169